We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Siemens Healthineers Introduces Autoanalyzer Assay for Monitoring Fentanyl Usage

By LabMedica International staff writers
Posted on 28 Jan 2020
A recently introduced diagnostic test for use on clinical chemistry autoanalyzers measures the levels of the opioid drug fentanyl and its primary metabolite norfentanyl.

Fentanyl is a synthetic opioid similar to morphine, prescribed for patients with chronic pain, post-operative pain, or treatment of breakthrough pain in cancer patients. More...
The [U.S.] Centers for Disease Control and Prevention has described fentanyl as being a synthetic opioid that is 50 times more potent than heroin and 100 times more potent than morphine.

There are two types of fentanyl: pharmaceutical fentanyl is prescribed to manage severe pain in cancer and surgical patients and end-of-life palliative care. Non-pharmaceutical fentanyl, or illicitly manufactured fentanyl, is often mixed with heroin and/or cocaine - with or without the user’s knowledge. Addictive cocktails incorporating illicitly manufactured fentanyl have evolved into the leading cause of drug overdose death.

When consumed, fentanyl is metabolized to norfentanyl and other metabolites. About 90% of the dose is excreted in urine as norfentanyl, while parent fentanyl accounts for less than 7%.

Siemens Healthineers (Erlangen, Germany) is now distributing the ARK Fentanyl Assay, which provides laboratories with a greater window to screen for fentanyl. The ARK Fentanyl Assay is 510(k) approved for diagnostic use by the [U.S.] Food and Drugs Administration and is CE Marked for use in Europe. The assay measures nanogram per milliliter levels of fentanyl and norfentanyl in 23 microliter urine samples and generates results after only seven minutes. It is available for automated clinical chemistry analyzers offered by Siemens Healthineers including on the Atellica Solution, Viva Systems, Dimension and Dimension Vista Systems.

“Fentanyl testing provides necessary clinical information for more effective patient care where a gap currently exists. Adding the ARK Fentanyl Assay to the Atellica Solution menu offers laboratories an extensive drugs-of-abuse testing menu which can be run efficiently on a single instrument,” said Dr. Deepak Nath, president of laboratory diagnostics at Siemens Healthineers. “It also empowers laboratories to help identify exposure and addiction in their communities, and aid clinicians in getting patients on the path to treatment.”

Related Links:
Siemens Healthineers


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Thyroid Test
Anti-Thyroid EIA Test
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.